Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Falanga A; Gal GL; Carrier M; Abdel-Razeq H; Ay C; Martin AJM; Rocha ATC; Agnelli G; Elalamy I; Brenner B.

Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives.

Th Open : Companion Journal To Thrombosis And Haemostasis. 2021; 5(3): [doi:10.1055/s-0041-1736037]

Sereno, M; Jimenez-Gordo, AM; Baena-Espinar, J; Aguado, C; Mielgo, X; Pertejo, A; Alvarez-Alvarez, R; Sanchez, A; Lopez, JL; Molina, R; Lopez-Alfonso, A; Hernandez, B; Chiara, LE; Martin, AM; Lopez-Martin, A; Dorta, M; Collazo-Lorduy, A; Casado, E; de Molina, AR; Colmenarejo, G.

A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A Comparative Analysis

Cancers. 2021; 13(16): Nº de citas: 12 [doi:10.3390/cancers13164205]

Mandala, M; Larkin, J; Ascierto, PA; Del Vecchio, M; Gogas, H; Cowey, CL; Arance, A; Dalle, S; Schenker, M; Grob, JJ; Chiarion-Sileni, V; Marquez, I; Butler, MO; Di Giacomo, AM; Lutzky, J; De la Cruz-Merino, L; Atkinson, V; Arenberger, P; Hill, A; Fecher, L; Millward, M; Khushalani, NI; de Pril, V; Lobo, M; Weber, J.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

Journal for ImmunoTherapy of Cancer. 2021; 9(8): Nº de citas: 12 [doi:10.1136/jitc-2021-003188]

Gutierrez-Seijo, A; Garcia-Martinez, E; Barrio-Alonso, C; Pareja-Malagon, M; Acosta-Ocampo, A; Fernandez-Santos, ME; Puig-Kroger, A; Parra-Blanco, V; Mercader, E; Marquez-Rodas, I; Aviles-Izquierdo, JA; Samaniego, R; Sanchez-Mateos, P.

CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma

Cancers. 2021; 13(16): Nº de citas: 8 [doi:10.3390/cancers13163943]

Villalvazo, P; Marzal-Alfaro, B; Garcia-Alfonso, P; Revuelta-Herrero, JL; Thomas, F; Lopez-Tarruella, S; Garcia-Gonzalez, X; Calvo, A; Yakoubi, M; Salvador-Martin, S; Lopez-Lopez, F; Aguilar, I; Sanjurjo-Saez, M; Martin, M; Lopez-Fernandez, LA.

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Journal Of Personalized Medicine. 2021; 11(8): Nº de citas: 5 [doi:10.3390/jpm11080792]

Slamon, DJ; Neven, P; Chia, S; Jerusalem, G; De Laurentiis, M; Im, S; Petrakova, K; Bianchi, GV; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Ji, Y; Wang, C; Deore, U; Chakravartty, A; Zarate, JP; Taran, T; Fasching, PA.

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

ANNALS OF ONCOLOGY. 2021; 32(8): 1015-1024 Nº de citas: 192 [doi:10.1016/j.annonc.2021.05.353]

Polley, MYC; Dickler, MN; Sinnwell, J; Tenner, K; de la Haba, J; Loibl, S; Goetz, MP; Bergh, J; Roberston, J; Couch, F; Ellis, MJ; Martin, M.

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

BREAST CANCER RESEARCH AND TREATMENT. 2021; 189(1): 15-23 Nº de citas: 5 [doi:10.1007/s10549-021-06319-z]

Astorga, BG; Ballabrera, FS; Aguilar, EA; Fernandez, EE; Garcia-Alfonso, P; Flores, EG; Garcia, RV; Montes, AF; Munoz, AML; Salvia, AS.

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(8): 1520-1528 Nº de citas: 4 [doi:10.1007/s12094-021-02568-y]

Garrido, P; Hladun, R; de Alava, E; Alvarez, R; Bautista, F; Lopez-Rios, F; Colomer, R; Rojo, F.

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(8): 1529-1541 Nº de citas: 15 [doi:10.1007/s12094-021-02558-0]

Escudero-Vilaplana, V; Collado-Borrell, R; del Monte-Millan, M; Hoyo-Munoz, A; Martinez-Sagrera, PG; Revuelta-Herrero, JL; Marzal-Alfaro, B; Gonzalez-Haba, E; Cobo, SLT; Gilarranz, YJ; Herranz, A; Sanjurjo, M; Martin, M.

Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

SUPPORTIVE CARE IN CANCER. 2021; 29(8): 4673-4681 Nº de citas: 1 [doi:10.1007/s00520-021-06016-z]

Jantus-Lewintre, E; Sureda, BM; Larriba, JLG; Rodriguez-Abreu, D; Juan, O; Blasco, A; Domine, M; Pulla, MP; Garde, J; Alvarez, R; Maestu, I; de Carrion, RP; Artal, A; Rolfo, C; de Castro, J; Guillot, M; Oramas, J; de las Penas, R; Ferrera, L; Martinez, N; Serra, O; Rosell, R; Camps, C; Grp Espanol Canc Pulmon GECP.

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

Frontiers in Oncology. 2021; 11: 695038-695038 Nº de citas: 5 [doi:10.3389/fonc.2021.695038]

Aviles-Izquierdo, JA; Mercader-Cidoncha, E; Escat-Cortes, JL; Marquez-Rodas, I; Parra-Blanco, V; Rodriguez-Lomba, E.

When is it worth performing lymphadenectomy in patients with melanoma micrometastases? A 20-year experience retrospective analysis

CIRUGIA Y CIRUJANOS. 2021; 89(4): 457-460 [doi:10.24875/CIRU.20000545]

Curigliano, G; Martin, M; Jhaveri, K; Beck, JT; Tortora, G; Fazio, N; Maur, M; Hubner, RA; Lahner, H; Donnet, V; Ajipa, O; Li, Z; Blumenstein, L; Andre, F.

Clinical Trial

EUROPEAN JOURNAL OF CANCER. 2021; 151: 49-62 Nº de citas: 17 [doi:10.1016/j.ejca.2021.03.042]

Provencio, M; Gallego, JMM; Calles, A; Antonanzas, M; Pangua, C; Rubio, XM; Nadal, E; Castro, RL; Lopez-Martin, A; Del Barco, E; Domine, M; Franco, F; Diz, P; Sandoval, C; Girona, ES; Sullivan, I; Sala, MA; Ledo, GG; Cucurull, M; Mosquera, J; Martinez, M; Chara, LE; Arriola, E; Herrera, BE; Jarabo, JR; Alvarez, RA; Baena, J; Cao, MG.

Lung cancer patients with COVID-19 in Spain: GRAVID study

LUNG CANCER. 2021; 157: 109-115 Nº de citas: 30 [doi:10.1016/j.lungcan.2021.05.014]

Johnston, S; O'Shaughnessy, J; Martin, M; Huober, J; Toi, M; Sohn, J; Andre, VAM; Martin, HR; Hardebeck, MC; Goetz, MP.

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Npj Breast Cancer. 2021; 7(1): 80-80 Nº de citas: 41 [doi:10.1038/s41523-021-00289-7]

Romera, A; Cebollero, M; Romero-Gomez, B; Carricondo, F; Zapatero, S; Garcia-Aldao, U; Martin-Albo, L; Ortega, J; Vara, E; Garutti, I; Simon, C.

Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery

Biomed Research International. 2021; 2021: 6630232-6630232 Nº de citas: 7 [doi:10.1155/2021/6630232]

Illini, O; Hochmair, MJ; Fabikan, H; Weinlinger, C; Tufman, A; Swalduz, A; Lamberg, K; Hashemi, SMS; Huemer, F; Vikstrom, A; Wermke, M; Absenger, G; Addeo, A; Banerji, S; Calles, A; Clarke, S; Di Maio, M; Durand, A; Duruisseaux, M; Itchins, M; Kaaranien, OS; Krenn, F; Laack, E; de Langen, AJ; Mohorcic, K; Pall, G; Passaro, A; Prager, G; Rittmeyer, A; Rothenstein, J; Schumacher, M; Woll, E; Valipour, A.

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Therapeutic Advances in Medical Oncology. 2021; 13: Nº de citas: 43 [doi:10.1177/17588359211019675]

Hamilton, E; Cortes, J; Ozyilkan, O; Chen, SC; Petrakova, K; Manikhas, A; Jerusalem, G; Hegg, R; Huober, J; Chapman, SC; Lu, Y; Hardebeck, MC; Bear, MM; Johnston, EL; Martin, M.

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

CLINICAL BREAST CANCER. 2021; 21(3): 181 Nº de citas: 30 [doi:10.1016/j.clbc.2020.09.011]